Phaseline

Targets › HHLA2

HHLA2 (HERV-H LTR-associating protein 2): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Aug 2027.

Through interaction with TMIGD2, costimulates T-cells in the context of TCR-mediated activation. Enhances T-cell proliferation and cytokine production via an AKT-dependent signaling cascade. (UniProt, Q9UM44)

Open in Phaseline: the race on HHLA2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
NextPoint TherapeuticsNPX887
B7-H7/HHLA2 antagonistic monoclonal antibody
HHLA2Phase 1Metastatic Malignant NeoplasmAug 2027

Conditions

Metastatic Malignant Neoplasm (1)

Modalities

small molecule (1)

Companies

NextPoint Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.